Search result: Catalogue data in Autumn Semester 2018
|Core Courses I|
|535-0011-00L||Drug Seminar |
The course is reserved for students registered in the Master's programme in Pharmacy or in Pharmaceutical Sciences
|O||5 credits||9S||M. Detmar, K.‑H. Altmann, S. M. Ametamey, B. A. Gander, C. Halin Winter, J. Hall, S.‑D. Krämer, J.‑C. Leroux, C. Müller, D. Neri, V. I. Otto, U. Quitterer, R. Schibli, G. Schneider, C. Steuer, H. U. Zeilhofer|
|Abstract||The course provides a platform for the investigation, presentation and discussion of a topic with relevance to the field of pharmaceutical sciences. Students work in small groups on a chosen topic, they write a mini-review and present their work on a one day symposium.|
|Objective||The main objectives of this course are: |
- students develop their scientific reflection (Critical Thinking) and working skills by working independently on a relevant pharmaceutical topic
- students gain in-depth knowledge of the topic investigated
- students train their scientific writing and presentation skills
- students train their ability to plan a project and work in a team
|Content||The Course Drug Seminar takes place during the first 7 weeks of the 1. Master semester. It is a compulsory course of the MSc Pharmacy curriculum and an elective course in the MSc PharmSciences. |
The course provides a platform for the investigation, presentation and discussion of a topic with relevance to the field of pharmaceutical sciences.
During the course, students work in small teams on a topic of their choice and elaborate a written mini-review and an oral presentation. Each team is tutored by a lecturer of the Institute of Pharmaceutical Sciences. The work is mainly based on literature search / review, but may also involve conducting interviews or site visits, if appropriate. The final presentations of all groups will take place in the framework of a dedicated Symposium held in the middle of the semester.
|Prerequisites / Notice||Only for students of MSc Pharmacy and MSc Pharmaceutical Sciences.|
|535-0041-00L||Pharmacology and Toxicology III||O||2 credits||2G||M. Detmar, U. Quitterer|
|Abstract||The course is divided into two parts. The first part provides a detailed understanding of drugs and pharmacotherapy of infectious diseases and cancer. The second part gives an overview of the field of pharmacogenomics with a special focus on the role of genetic polymorphisms in disease susceptibility, drug response and adverse effects.|
|Objective||The course advances basic knowledge in pharmacology and toxicology. Special emphasis is placed on the interrelationship between pharmacological, pathophysiological and clinical aspects of drug therapy in the fields of infectious diseases and cancer. The course also provides an overview of the field of pharmacogenomics, with a special focus on the role of genetic polymorphisms in disease susceptibility, drug response and adverse effects.|
|Content||Topics include the pharmacology and pharmacotherapy of infectious diseases and cancer. In the field of pharmacogenomics, the course is focused on genetics, genome-wide association studies, genetic disease predisposition, examples of genetic variability of drug metabolism and drug responses, identification of new drug targets, relevance of pharmacogenomics for clinical drug development, and toxicogenomics.|
|Lecture notes||A script is provided for each lecture course. The scripts define important and exam-relevant contents of lectures. Scripts do not replace the lecture.|
|Literature||Recommended reading: |
The classic textbook in Pharmacology:
Goodman and Gliman`s The Pharmacological Basis of Therapeutics
Laurence Brunton, Bjorn Knollman, Randa Hilal-Dandan.
13th edition (2017)
Klaus Aktories, Ulrich Förstermann, Franz Hofmann, Klaus Starke.
Allgemeine und spezielle Pharmakologie und Toxikologie.
12th edition (2017)
Urban & Fischer (Elsevier, München)
|535-0050-00L||Pharmacoepidemiology and Drug Safety||O||3 credits||2G||S. Russmann|
|Abstract||Introduction to the principles, methods and applications of pharmacoepidemiology and drug safety. Drug safety in the pharmaceutical industry and regulatory authorities, but also for hospital and office pharmacists. Another focus is the evaluation and interpretation of pharmacoepidemiological drug safety studies in the medical literature and the evaluation of benefits vs. risks.|
- To familiarize participants with the principle methods and applications of pharmacoepidemiology and drug safety that is relevant for industry, regulatory affairs, but also for clinical pharmacists in hospitals and office pharmacies.
- Perform independently a causality assessment of suspected adverse drug reactions in patients
- Study designs and biostatistics used for the quantitative evaluation of drug safety
- Setup of programs that can effectively reduce medication errors and improve drug safety in clinical practice, particularly in hospitals
|Content||- Historical landmarks of drug safety|
- Pharmacovigilance and causality assessment
- Drug safety in premarketing clinical trials
- Descriptive, cohort and case-control drug safety study designs; Data analysis and control of confounding
- Pharmacoepidemiology and regulatory decision making in drug safety; Risk management plans (RMPs)
- Medication errors, clinical pharmacology / clinical pharmacy
- Clinical Decision Support Systems, Interventional Pharmacoepidemiology
- Pharmacoepidemiological databases, 'Big Data'
- Interactive discussion of many real-life examples for each topic
|Lecture notes||This course will be a combination of formal lectures, group discussions and self-directed studies. Course material will be taught through seminars, case studies in small groups.|
Reading material and scripts will be provided for each week.
- Rothman: Introduction to Epidemiology
- Strom, Kimmel, Hennessy: Textbook of Pharmacoepidemiology
- Gigerenzer: Risk Savvy - How to Make Good Decisions
|535-0030-00L||Therapeutic Proteins||O||3 credits||3G||C. Halin Winter, D. Neri|
|Abstract||In this course, various topics related to the development, GMP production and application of therapeutic proteins will be discussed. Furthermore, students will expand their training in pharmaceutical immunology and will be introduced to the basic concepts of pharmaceutical product quality management.|
|Objective||Students know and understand: |
- basic mechanisms and regulation of the immune response
- the pathogenic mechanisms of the most important immune-mediated disorders
- the most frequently used expression systems for the production of therapeutic proteins
- the use of protein engineering tools for modifying different features of therapeutic proteins
- the mechanism of action of selected therapeutic proteins and their application
- basic concepts in the GMP production of therapeutic proteins
|Content||The course consists of two parts: |
In a first part, students will complete their training of pharmaceutical immunology (Chapter 13 - 16 Immunobiology VIII textbook). This part particularly focuses on the pathogenic mechanisms of immune-mediated diseases. Deepened knowledge of immunology will be relevant for understanding the mechanism of action of many therapeutic proteins, as well as for understanding one major concern related to the use of protein-based drugs, namely, immunogenicity.
The second part focuses on topics related to the development and application of therapeutic proteins, such as protein expression, protein engineering, reducing immunogenicity, and GMP production of therapeutic proteins. Furthermore, selected examples of approved therapeutic proteins will be discussed.
|Lecture notes||Handouts to the lectures will be available for downloading under http://www.pharma.ethz.ch/scripts/index|
|Literature||- Janeway's ImmunoBiology, by Kenneth Murphy (9th Edition), Chapters 12-16|
- Lecture Handouts
- Paper References provided in the Scripts
- EMEA Dossier for Humira
|535-0137-00L||Clinical Chemistry II||O||1 credit||1V||M. Hersberger|
|Abstract||Detailed knowledge on particular aspects of clinical chemistry and medical laboratory diagnostics concerning quality control, point-of-care analytics, analytics of kidney stones, tumor markers, diagnosis of HIV and hepatitis, pharmacogenetics, thyroid function, bone metabolism and laboratory diagnosis of hypertension.|
|Objective||Detailed knowledge on the implementation and interpretation of clinical laboratory diagnostic tests. Competence to interprete selected tests.|
|Content||Internal and external quality control, point-of-care analytics, analytics of kidney stones, use of tumor marker determinations, diagnosis of HIV and hepatitis, pharmacogenetics, thyroid function, bone metabolism and laboratory diagnosis of hypertension.|
|Lecture notes||Documentation will be available before the lectures electronically.|
|Literature||- Jürgen Hallbach, Klinische Chemie und Hämatologie für den Einstieg, Thieme Verlag|
- Harald Renz, Praktische Labordiagnostik, de Gruyter Verlag
- Walter Guder, Das Laborbuch für Klinik und Praxis, Elsevier Verlag
- Lothar Thomas, Labor und Diagnose, TH Books
- William Marshall, Clinical Chemistry, Mosby Ltd.
- Alan H.B. Wu, Tietz, Clinical Guide to Laboratory Tests, Saunders
|Prerequisites / Notice||Requirement: basic knowledge in clinical chemistry and laboratory diagnostics|
|Core Courses (Clinical Subjects)|
|535-5512-00L||Triage, Diagnostics, Therapy Support||O||9 credits||12G||E. Kut Bacs, S. Erni, A. Küng Krähenmann, D. Petralli-Nietlispach, K. Prader-Schneiter, I. S. Vogel Kahmann, P. Wiedemeier|
|Abstract||This course provides basic clinical and pharmaceutical knowledge and skills for triage, diagnostics and therapy support of the most common diseases.|
• know and understand the pathomechanisms and clinical lead and warning symptoms (red flags) of the most common diseases in the fields listed below.
• can use this knowledge to triage patients: i.e. analyse simple symptoms and diseases, make a tentative diagnosis and recommend suitable medication or further examinations or measures.
• know the therapeutic guidelines, classes of active ingredients and selected, practice-relevant drugs (including indications and the most frequent and important dosages, adverse drug reactions, interactions and contraindications).
|Content||"Pharmaceutical Care" und "Health Care";|
Häufigste Erkrankungen und Therapien der
- Angiologie und Hämatologie
- Endokrinologie und Diabetologie
Grundlagen ausgewählter nichtmedikamentöser Therapiemethoden (z.B. Physiotherapie)
|Lecture notes||Provided via myStudies.|
|Literature||As stated in the lecture notes.|
|Prerequisites / Notice||Please note that the assessment of this course must be passed (not compensable).|
The courses Pharmacology and Toxicology I and II and Pathobiology provide indispensable basics which students must master at the beginning of the semester in order to successfully complete the course.
Pharmacology and Toxicology III must be visited at the same time.
|535-0423-00L||Drug Delivery and Drug Targeting||W||2 credits||1.5V||J.‑C. Leroux, B. A. Gander, A. Spyrogianni Roveri|
|Abstract||The students gain an overview on current principles, methodologies and systems for controlled delivery and targeting of drugs. This enables the students to understand and evaluate the field in terms of scientific criteria.|
|Objective||The students dispose of an overview on current principles and systems for the controlled delivery and targeting of drugs. The focus of the course lies on developing a capacity to understand the involved technologies and methods, as well as an appreciation of the chances and constraints of their therapeutic usage, with prime attention on anticancer drugs, therapeutic peptides, proteins, nucleic acids and vaccines.|
|Content||The course covers the following topics: drug targeting and delivery principles, macromolecular drug carriers, liposomes, micelles, micro/nanoparticles, gels and implants, administration of vaccines, targeting at the gastrointestinal level, synthetic carriers for nucleic acid drugs, ophthalmic devices and novel trends in transdermal and nasal drug delivery.|
|Lecture notes||Selected lecture notes, documents and supporting material will be directly provided or may be downloaded using|
The website also displays additional information on peroral delivery systems, transdermal systems and systems for alternative routes (nasal, pulmonary) of delivery. These fields are covered in detail in the course Galenische Pharmazie II (Galenical Pharmacy II).
|Literature||A.M. Hillery, K. Park. Drug Delivery: Fundamentals & Applications, second edition, CRC Press, Boca Raton, FL, 2017.|
B. Wang B, L. Hu, T.J. Siahaan. Drug Delivery - Principles and Applications, second edition, John Wiley & Sons, Hoboken NJ, 2016.
Y. Perrie, T. Rhades. Pharmaceutics - Drug Delivery and Targeting, second edition, Pharmaceutical Press, London and Chicago, 2012.
Further references will be provided in the course.
|535-0250-00L||Biotransformation of Drugs and Xenobiotics||W||1 credit||1V||S.‑D. Krämer|
|Abstract||Knowledge of the major reactions of biotransformation in drug therapy, prediction of possible metabolites of drugs and xenobiotics, recognition of structure elements and reactions which can lead to toxic metabolites. Knowledge of inter- and intraindividual factors influencing metabolism.|
|Objective||Goals: knowledge of the major reactions of biotransformation in drug therapy, prediction of possible metabolites of drugs and xenobiotics, recognition of structure elements and reactions which can lead to toxic metabolites. Knowledge of inter- and intraindividual factors influencing metabolism.|
|Content||Major reactions of biotransformation. Major enzymes and reaction partners involved in the biotransformation of drugs and xenobiotics. Toxic reactions of metabolites. Factors which affect the biotransformation.|
|Lecture notes||Biotransformation of drugs and xenobiotics|
|Literature||B. Testa and S.D. Krämer. The Biochemistry of Drug Metabolism: Volumes 1 and 2, VHCA, Zürich, 2008 and 2010.|
B. Testa and S.D. Krämer. The Biochemistry of Drug Metabolism: Parts 1 to 7. Published in Chemistry & Biodiversity, 2006-2009.
|535-0546-00L||Patents||W||1 credit||1V||A. Koepf, P. Pliska|
|Abstract||Knowledge in the field of intellectual property, especially of patents and trademarks, with particular emphasis on pharmaceutics.|
Introduction into intellectual property; prosecution of patent applications; patent information; exploitation and enforcement of patents; peculiarities in pharmaceutics and medicine; social, political and ethical aspects; Trademarks.
|Objective||Basic knowledge in the field of industrial property, especially of patents and trademarks, with particular emphasis on the chemical, pharmaceutical and biotech field.|
|Content||1. Introduction into industrial property (patents, trademarks, industrial designs);|
2. Prosecution of patent applications (patentability);
3. Patent information (patent publications, databases, searches);
4. Exploitation and enforcement of patents (possibilities of exploitation, licenses, parallel imports, scope of protection, patent infringement);
5. Peculiarities in pharmaceutics and medicine (supplementary protection certificates, experimental use exemption, therapy and diagnosis, medical indication);
6. Social, political and ethical aspects (patents and prices for medicinal products, traditional knowledge and ethnomedicine, bioprospecting and biopiracy, human DNA inventions);
7. Trademarks, types of trademarks, grounds for refusal, peculiarities of pharma-trademarks.
|Lecture notes||A script is provided in electronic form during the lecture.|
|Literature||- Swiss Patents Act: http://www.admin.ch/ch/d/sr/c232_14.html|
- Swiss Trademarks Act: http://www.admin.ch/ch/d/sr/c232_11.html
- Swiss Industrial-Designs Act: http://www.admin.ch/ch/d/sr/c232_12.html
- European Patent Convention: http://www.epo.org/law-practice/legal-texts/html/epc/2010/e/ma1.html
- Patent Cooperation Treaty: http://www.wipo.int/pct/en/texts/articles/atoc.htm
- Swiss Federal Institute of Intellectual Property: https://www.ige.ch/en.html
- European Patent Office: http://www.epo.org/index.html
- World Intellectual Property Organization: http://www.wipo.int/portal/index.html.en
|535-0015-00L||History of Pharmacy||W||1 credit||1V||M. Fankhauser|
|Abstract||The students will receive the basic knowledge of the history of pharmacy. This knowledge will allow them to have a detailled approach to the actual pharmacy and the development of the materia medica.|
|Objective||The students will receive the basic knowledge of the history of pharmacy. This knowledge will allow them to have a detailled approach to the actual pharmacy and the development of the materia medica.|
|Content||In the first part of the lecture we will talk about the position of the pharmacist in the past and in society. We go through the milestones of the social and legal development of pharmacy. The second part will deal with the history of pharmacology with development of therapeuctical theories and the evolution of the used remedies. It also includes their sometimes mystical and symbolical dimension.|
|Literature||Wird in der ersten Veranstaltung mitgeteilt.|
|Prerequisites / Notice||Voraussetzungen: Keine. Interesse für die Rolle der Pharmazie und der Medikamente in der Vergangenheit von Vorteil.|
|535-0344-00L||From Ethnopharmacy to Molecular Pharmacognosy||W||1 credit||1V||B. Frei Haller, J. Gertsch|
|Abstract||Basic understanding and awareness of ethnopharmaceutical and ethnopharmacological issues and research. Knowledge of methods used in drug discovery from natural sources. Discussion of the issues around law and international treaties. Importance of ethnopharmaceutical knowledge for world health.|
|Objective||Basic understanding and awareness of ethnopharmaceutical and ethnopharmacological issues and research. Knowledge of methods used in drug discovery from natural sources. Discussion of the issues around law and international treaties. Importance of ethnopharmaceutical knowledge for world health.|
|Content||Introduction into ethnopharmacy and related disciplines: definitions of terms, working methods, research projects, bioprospecting. Traditional medicinal plants of different cultures and their role in modern Western medicine (rational application of traditional uses), today's "fashion plants." Empirical, traditional knowledge versus Evidence Based Medicine. The role of biodiversity (CBD, Rio 1992; Nagoya, 2010) and problems associated with drug discovery from natural products. Screening strategies for drug discovery (random screening versus screening based on cultural, ecological, ethnopharmacological, chemotaxonomic criteria). Traditional knowledge in relation to the fight against malaria and its implementation in research, product development and development cooperation. Introduction to and selected examples of herbal drugs and poisons, mode of action, and their ethnopharmacological importance. Critical analysis of bioprospecting as a drug discovery strategy.|
|Lecture notes||Handouts will be provided.|
|Literature||Plants in Our World, Economic Botany (2014) Beryl B. Simpson; Molly Conner Ogorzaly, 4th ed. , MacGraw-Hill, Boston|
|Prerequisites / Notice||Prerequisites: Basic lectures in biology or biochemistry and pharmaceutical biology have been attended; not suitable for first semester students.|
|535-0300-00L||Molecular Mechanisms of Drug Actions and Targets |
Number of participants limited to 24.
|W||2 credits||1V||J. Scheuermann|
|Abstract||On average one drug per year is withdrawn from the market. Using selected examples of such drug failures, the course aims at analyzing and discussing the present explanations of drug actions as well as the design and predictive power of animal models and clinical trials. In addition, the ethical, societal, and economical expectations in new drugs shall be reflected and discussed.|
|Objective||To develop a critical understanding of the relevance and limitations of the current approaches to explaining and anticipating drug effects. To critically appraise the ethical, societal, economical and political expectations in the development of new drugs.|
|Content||In December 2006, Pfizer stopped a large phase III study on the use of Torcetrapib for the prevention of atherosclerosis and cardiovascular disease. 800 million $ in development costs and 21 billion $ in stocks were annihilated overnight. The failure of Torcetrapib has pinpointed the limitations of an extremely reductionist view of atherosclerosis and it's prevention by drug therapy. It has also highlighted what high expectations we have in a safe and wide applicability of drugs and of their economical success. |
Torcetrapib is not a single case. In the last 10 years, on average one drug per year was withdrawn from the market due to lack of efficacy, unexpected side effects or toxicity. This clearly shows that the common investigations and the modern understanding of drug actions are often not sufficient to predict the effects a drug will have in large patient populations.
These are the topics of the present course. Using three particularly informative examples of drug failures, the problems encountered and the concepts and informative value of preclinical and clinical studies will be analyzed and discussed. Furthermore, the ethical, societal, economical and political expectations in new drugs shall be reflected.
|Lecture notes||Printouts of the slides used for the lectures and literature for reading and discussions will be available online.|
|Literature||Recommended reading: John Abramson, Overdo$ed America, Harper Perennial, New York 2008|
|Prerequisites / Notice||Requirements: basic knowledge in Medicinal Chemistry and Pharmacology. Ability to read and understand scientific publications written in English.|
|535-0310-00L||Glycobiology in Drug Development||W||1 credit||1V||V. I. Otto|
|Abstract||Protein-based drugs constitute around 25% of new approvals and most of them are glycoproteins. Using selected examples of prominent glycoprotein drugs, the course aims at providing insight into glycosylation-activity relationships and into biotechnological production and analytics.|
|Objective||Students gain insight into the glycobiology of therapeutically used glycoproteins. This implies knowing and understanding|
- the major types of protein-linked glycans and their biosynthesis
- the most important expression systems for production of recombinant glycoproteins
- methods used to alter or manipulate glycosylation
- the most prominent clinically used glycoproteins and how glycosylation influences their therapeutic profile.
- Current methods for the qualitative and quantitative characterization of glycoproteins
Students are able to apply this knowledge and propose solutions to biotechnological problems that involve protein glycosylation.
1. Glycans - information carriers in biology and pharmacotherapy
2. Glucocerebrosidase and the biosynthesis of N-glycans
3. Glyocerebrosidase - production and quality control
4. Improving the therapeutic profile of monoclonal antibodies by glycoengineering
5. Sialylation and mucin-type O-glycans as critical quality attributes of glycoprotein hormones and drugs
6. EPO "the same but different"
The lectures will include some exercises in which students apply their knowledge to solve simple biotechnological problems related to protein glycosylation.
|Lecture notes||The slides used for the lectures will be provided online|
|Literature||- Essentials of Glycobiology 3rd edition, A. Varki, R.D. Cummings et al., Cold Spring Harbor Laboratory Press, New York 2017.|
- Posttranslational Modification of Protein Biopharmaceuticals, G. Walsh (ed.), Wiley VCH, Weinheim 2009.
- Gentechnik, Biotechnik. Grundlagen und Wirkstoffe, 2. Auflage, Dingermann, Winckler, Zündorf, Wissenschaftliche Verlagsgesellschaft Stuttgart, 2011.
|Prerequisites / Notice||Requirements: Basic knowledge in immunology, molecular biology, protein chemistry and analytics. Basic knowledge in pharmacology.|
|535-0021-00L||Vitamins in Health and Disease||W||1 credit||1V||C. Müller|
|Abstract||Vitamins are essential organic compounds that cannot be synthesized by an organism and hence, thy have to be acquired from the diet. This lecture will give an overview about the application of vitamins in health and disease.|
|Objective||The aim of this lecture is a critical examination of the students with the topic of "Vitamins in Health and Disease". The students will get an overview of vitamins, of their medical applications and the role of the pharmacist with "over-the-counter" products.|
|Content||Deficiencies of particular vitamins result in specific diseases such as for example scurvy (vitamin C deficiency). Such disease patterns are usually easily recognized and facile to be treated. The clinical utility of supplementation concerns people with severe deficiencies and a risk of complications. Latent vitamin deficiencies might result in variable disorders and risks. As an example neurological disorders in elderly as a consequence of chronic lack of vitamin B12 should be mentioned. Subclinical deficiencies are often difficult to assess. However, these are exactly the cases where advice of a pharmacist is requested.|
A large intake of vitamins by over-supplementation or food fortification might be dangerous (hypervitaminosis). This is in particular the case for fat-soluble vitamins or in the case of constant intake of high amounts of water-soluble vitamins over a long time period.
The lecture 'Vitamins in Heath and Disease' will give an overview over the history and applications of vitamins and their functions to preserve good health. The utility of vitamin supplementation during conditions of deficiencies, potential consequences of a latent deficiency as well as risks of over-supplementation will be discussed.
|Lecture notes||Hand-outs will be distributed during the lecture (partly in English, partly in German).|
|Literature||Book recommendation: reference books:|
- Handbuch Nährstoffe, Burgerstein,
Trias Verlag ISBN 978-3-8304-6071-8
Arzneimittel und Mikronährstoffe - Medikationsorientierte Supplementierung
WVG, ISBN 978-3-8047-2779-3
|Prerequisites / Notice||Requirements: Basic knowledge in biochemistry and pharmacology. Ability to read and understand scientific publications in English.|
|535-0360-00L||Evidence Based Phytotherapy||W||1 credit||1V||J. Drewe, K. Berger Büter|
|Abstract||Based on epidemiology, economic importance and evidence-based medicine, basic principles of rational phytotherapy will be discussed: a) Identification of drug candidates, b) registration requirements, c) criteria to assess efficacy, d) biomarkers and pharmacokinetics, e) safety and f) principles of extract generation. Important prototypes will be discussed|
|Objective||Students should learn the importance of rational (= evidence based) pharmacotherapy with herbal extracts:|
They should get to know the development process of herbal drugs:
o How are interesting development candidates are being identified? What are the strategies?
o What are the regulatory requirements (traditional use, well-established use, new herbal entities)?
o What are the selection criteria?
o Assessment of efficacy (animal-/human studies, biomarker)
o Safety (Toxicity, unwanted adverse effects, drug-drug interactions)
o Pharmaceutical quality
o Securing of herbal identity (collections, agriculture)
o Quality management
o selection of appropriate extraction procedures?
pes will be presented and critically discussed:
|Content||Effektive Zeiten 14.45 - 15.30; 15.45-16.30)|
Qualität Arzneipflanzen-Fertigprodukte, Monographien (Kommission E, ESCOP, HMPC), Unterschiede hinsichtlich des Registrierungsstatus und -anforderungen: traditional use, well established use und new herbal entities, Methoden Produktentwicklung (Pflanzenauswahl, Anbau, Extraktentwicklung, präklinische und klinische Entwicklung)
Grundlegende Begriffe der evidenzbasierten Medizin
Hypericum perforatum (inklusive Pyrrolizidinalkaloid Problematik
Petasites (inklusive Pyrrolizidinalkaloid-Problematik)
|Lecture notes||Die Skripten werden vor den jeweiligen Vorlesungen per Email an die Teilnehmer versandt|
|535-0022-00L||Computer-Assisted Drug Design||W||1 credit||1V||G. Schneider|
|Abstract||The lecture series provides an introduction to computer applications in medicinal chemistry. A focus is on molecular representations, property predictions, molecular similarity concepts, virtual screening techniques, and de novo drug design. All theoretical concepts and algorithms presented are illustrated by practical applications and case studies|
|Objective||The students will learn how computer simulation generates ideas for drug design and development, understand the theoretical principles of property prediction and computer-generated compound generation, and understand possibilities and limitations of computer-assisted drug design in pharmaceutical chemistry. As a result, they are prepared for professional assessment of computer-assisted drug design studies in medicinal chemistry projects.|
|Literature||Recommended textbooks: |
1) G. Schneider, K.-H. Baringhaus (2008) "Molecular Design - Concepts and Applications", Wiley-VCH: Weinheim, New York.
2) H.-D. Höltje, W. Sippl, D. Rognan, G. Folkers (2008) "Molecular Modeling: Basic Principles and Applications", Wiley-VCH: Weinheim, New York.
3) G. Klebe (2009) "Wirkstoffdesign", Spektrum Akademischer Verlag: Heidelberg.
|Prerequisites / Notice||Successful participation in this course is required for a research project ("Forschungspraktikum") in the CADD group.|
|535-0024-00L||Methods in Drug Design |
Complementary to the practical course "Computer-Assisted Drug Design (Practical Course)" 535-0023-00L . Compulsory for the students of the practical course, open for other interested students.
|W||1 credit||1V||G. Schneider|
|Abstract||The lecture is organized as a two-week block during the practical course "Computer-Assisted Drug Design" (535-0023-00 P), totalling 10 two-hour lectures. It provides an introduction to advanced drug design techniques and approaches emphasizing computer-assisted molecular design.|
|Objective||Participants will learn about computational algorithms and advanced experimental approaches to drug discovery and design, including selected actual topics and practical applications. The contents of the lecture will allow for a deeper understanding of modern computer-assisted drug design methods and how they are linked to experimental applications. The main focus is on computational medicinal chemistry, so that participants will be able to use relevant computer-based methods in own research projects.|
|Literature||Schneider, G. and Baringhaus, K.-H. (2008) Molecular Design - Concepts and Applications. Wiley-VCH, Weinheim, New York.|
Additional selected literature will be provided during the lecture.
|Prerequisites / Notice||The lecture is mandatory for all participants of the course "Computer-Assisted Drug Design" (535-0023-00 P).|
|535-0023-00L||Computer-Assisted Drug Design (Practical Course) |
Limited number of participants.
|W||4 credits||6P||G. Schneider, J. A. Hiss|
|Abstract||The practical course is open for master and graduate students to get an introduction into hands-on computer-assisted drug design. The class includes an introduction to computer-based screening of a virtual compound library, subsequent synthesis of candidate ligands, and biochemically testing for activity on pharmacologically important drug targets.|
|Objective||Participants become familiar with state-of-the-art methodologies in a real-life computer-aided medicinal chemistry project. Participants work as small teams, perform literature research and discuss recent research findings. A seminar talk is to be given presenting the molecular design strategy chosen and the results obtained during the course.|
|Content||The course offers the possibility for people with and without computational and or laboratory background to get an introduction into computer-assisted drug design, as well as practical training in a modern chemical laboratory. Using various software suites, the participants will computationally create and screen a virtual compound library for potential active small molecules. The process will involve an introduction to screening a virtual compound library, synthesizing candidate inhibitors, and biophysical testing against a pharmacologically important drug target.|
|Lecture notes||Detailed information will be handed out during the course.|
Schneider, G. and Baringhaus, K.-H. (2008) Molecular Design - Concepts and Applications. Wiley-VCH, Weinheim, New York.
|Prerequisites / Notice||The class is organized as a two-week block course.|
The number of participants is limited.
Kick-off meeting and confirmation of registration (Vorbesprechung und Platzvergabe): During the last lecture of the class "Computer-Assisted Drug Design" (535-0022-00)
Ideally, students interested in the course participated and successfully passed the lecture "Computer-Assisted Drug Design" (535-0022-00).
|327-0811-00L||Industrial Research and Development at the Interface of Biomaterials and Drug Delivery|
Does not take place this semester.
|Abstract||This course will provide an up-to-date, comprehensive review of the industrial perspective at the interface of biomaterials and drugs. This covers regulatory, clinical, pre-clinical and manufacturing concepts. The presentations are provided in an effort to maximize the interaction of student and lecturer.|
|Objective||- The student will be able to categorize a drug-biomaterial as a "drug" or a "material" from a regulatory perspective and can summarize general regulatory pathways for material/drug development.|
- The student will be able to summarize the current concepts and challenges for the indstry at the material-drug interface.
- The student will actively develop innovative, industrial concepts at the drug-biomaterial interface.
|Content||This course will provide an up-to-date comprehensive review of the industrial perspective at the interface of biomaterials and drugs. General concepts related to regulatory affairs or such as cost-conscious planning of manufacturing processes will be covered by interactive case-studies and in close interaction between students and lecturers. The course covers the future at the biomaterial - implant interface - as it is seen by the industry today - and will be reviewed by experienced and long-standing faculty from industry with the aim to provide a balanced, insightful perspective. From that, clinical development concepts, regulatory pathways and real-life case studies will be discussed with the students. Finally the students - working in small groups of 4-5 - will outline a development pathway for an industrial project and present it to the course and in presence of all faculty to receive maximum feedback to their approaches. |
The student will become familiar with the major elements required for a successful development and which challenges have to be taken into account to translate an idea into a successful product.
|Practical Pharmacy I|
|535-5521-00L||Therapeutic Skills I||O||3 credits||3G||A. Küng Krähenmann, S. Erni, E. Kut Bacs, D. Petralli-Nietlispach, K. Prader-Schneiter, I. S. Vogel Kahmann, P. Wiedemeier|
|Abstract||Diese Lehrveranstaltung vermittelt Offizin-relevantes Grundwissen und dessen Anwendung in Nephrologie, Ernährung, Phytotherapie, Komplementärmedizin, Veterinärpharmazie, Wundversorgung und Pharmaceutical Care.|
|Objective||Studierende kennen und verstehen die Therapiekonzepte der genannten Themengebiete und deren Anwendung in der Offizin.|
(detaillierte Lernziele siehe Wegleitung)
• Pharmaceutical Care 2
|Lecture notes||Wird über myStudies zur Verfügung gestellt.|
|Literature||Gemäss Angabe in den Skripten|
- Page 1 of 2 All